Market Overview

CareDx Reported Positive Clinical Results For Its Kidney Transplant Blood Tests


CareDx, Inc. (NASDAQ: CDNA) revealed promising clinical performance of its AlloSure assay for the non-invasive surveillance of kidney transplant rejection, according to a note from analysts at Janney.

In patients studied as part of a DART clinical trial, CareDx’s “AlloSure” blood assay successfully detected heightened levels of donor-derived cell free DNA in subjects presenting kidney transplant rejection.

More details could follow if AlloSure is presented during kidney week at the American Society of Nephrologists this fall. Leveraging on the company's transplantation expertise and existing relationships cultivated over a multi-year period, cross-selling opportunities and new product rollouts may drive revenue acceleration starting in 2017.

CareDx closed up 2 percent at $5.04.

Latest Ratings for CDNA

Aug 2020Raymond JamesMaintainsStrong Buy
Aug 2020HC Wainwright & Co.MaintainsBuy
Jun 2020BTIGInitiates Coverage OnBuy

View More Analyst Ratings for CDNA
View the Latest Analyst Ratings


Related Articles (CDNA)

View Comments and Join the Discussion!

Posted-In: JanneyAnalyst Color Biotech Health Care Analyst Ratings General

Latest Ratings

CVNAB. Riley FBRDowngrades230.0
CNXCapital One FinancialInitiates Coverage On16.0
NVCRNorthland Capital MarketsInitiates Coverage On200.0
TSLACanaccord GenuityMaintains377.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at